Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2019 1
2020 5
2021 4
2022 2
2023 1
2025 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

15 results

Results by year

Filters applied: . Clear all
Page 1
The feasibility of Miltuximab®-IRDye700DX-mediated photoimmunotherapy of solid tumors.
Polikarpov DM, Campbell DH, Lund ME, Lu Y, Lu Y, Wu J, Walsh BJ, Zvyagin AV, Gillatt DA. Polikarpov DM, et al. Photodiagnosis Photodyn Ther. 2020 Dec;32:102064. doi: 10.1016/j.pdpdt.2020.102064. Epub 2020 Oct 15. Photodiagnosis Photodyn Ther. 2020. PMID: 33069874
We aimed to investigate whether anti-GPC-1 antibody Miltuximab (Glytherix Ltd., Sydney, Australia) can be conjugated with IR700 for PIT of solid tumors. ...
We aimed to investigate whether anti-GPC-1 antibody Miltuximab (Glytherix Ltd., Sydney, Australia) can be conjugated with IR700 for P …
Pharmacokinetics and Biodistribution of 89Zr-Miltuximab and Its Antibody Fragments as Glypican-1 Targeting Immuno-PET Agents in Glioblastoma.
Ghosh S, Fletcher NL, Huda P, Houston ZH, Howard CB, Lund ME, Lu Y, Campbell DH, Walsh BJ, Thurecht KJ. Ghosh S, et al. Mol Pharm. 2023 Mar 6;20(3):1549-1563. doi: 10.1021/acs.molpharmaceut.2c00760. Epub 2023 Jan 5. Mol Pharm. 2023. PMID: 36602058
Here, we investigate zirconium-89 ((89)Zr)-conjugated Miltuximab (a clinical stage anti-GPC-1 monoclonal antibody developed by GlyTherix, Ltd.) and engineered fragments for their potential as immuno-PET tracers to detect GPC-1(positive) GBM tumors in preclinical models. .. …
Here, we investigate zirconium-89 ((89)Zr)-conjugated Miltuximab (a clinical stage anti-GPC-1 monoclonal antibody developed by GlyTherix …
Safety and Tolerability of Relugolix in Combination with Abiraterone or Apalutamide for Treatment of Patients with Advanced Prostate Cancer: Data from a 52-Week Clinical Trial.
De La Cerda J, Belkoff L, Courtney KD, Diamond E, D'Olimpio J, Dunshee C, Gervasi L, Goodman M, Mittal K, Morris D, Sieber P, Tutrone R, Ryan M, Zhong Y, Ufer M, Shore N. De La Cerda J, et al. Target Oncol. 2025 Apr 4. doi: 10.1007/s11523-025-01139-3. Online ahead of print. Target Oncol. 2025. PMID: 40180682
15 results